Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 8/20 | 0.49 |
| ▸ | HTR1B | P28222 | 7/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 6/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26078617 | 0.86 | TAAR1 (0.47) | HTR1DHTR1BADRA1AADRA2CADRA1D | |
| SCHEMBL26078587 | 0.85 | HTR1D (0.53) | HTR1DHTR1BADRA1AADRA2CADRA1D | |
| SCHEMBL26078590 | 0.85 | HTR1D (0.50) | HTR1DHTR1BADRA1AADRA2CADRA1D | |
| SCHEMBL26078616 | 0.84 | HTR1D (0.49) | HTR1DHTR1BADRA1AADRA2CADRA1D | |
| SCHEMBL4986530 | 0.75 | ADRA1A (0.50) | HTR1DHTR1BADRA1AADRA2CADRA1D | |
| SCHEMBL4990257 | 0.75 | HTR1D (0.58) | HTR1DHTR1BADRA1AADRA2CADRA1D | |
| SCHEMBL14092053 | 0.74 | HTR1D (0.49) | HTR1DHTR1BADRA1AADRA2CADRA1D | |
| SCHEMBL26078546 | 0.74 | TAAR1 (0.48) | HTR1DHTR1BADRA1AADRA2CADRA1D | |
| SCHEMBL4990248 | 0.72 | HTR1D (0.55) | HTR1DHTR1BADRA1AADRA2CADRA1D | |
| SCHEMBL26078602 | 0.71 | TAAR1 (0.51) | HTR1DHTR1BADRA1AADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | ADRA1A, ADRB1, ADRA1D | HTR1D 47/4885HTR1B 105/4885ADRA1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.